Financial Data and Key Metrics Changes - The company reported an 8% revenue growth for the quarter, with adjusted earnings per share increasing by 38% year over year [4][16] - Operating margin expanded by 450 basis points, driven by higher revenue and cost efficiencies [4][19] - Gross margin was 62.2%, a decline of 70 basis points year over year due to tariff impacts [18] Business Line Data and Key Metrics Changes - Healthcare revenue reached $371 million, representing an 8% growth [16] - Consumables grew by 1% this quarter, compared to a 20% growth in the same quarter last year [16] - Capital equipment and other revenues grew by 67% this quarter, rebounding from a 33% decline last year [16] Market Data and Key Metrics Changes - Incremental value of new contracts secured in the third quarter was $124 million, marking a 48% year-over-year increase [17] - Unrecognized contract revenue expected to be realized within the next 12 months was $507 million, a 17% year-over-year increase [17] Company Strategy and Development Direction - The company is focusing on three waves of growth: elevating commercial excellence, accelerating intelligent monitoring, and innovating wearables [9][10] - A strategic partnership with Philips was expanded, aiming to increase market share within Philips' installed base [5][32] - The company is investing in AI and machine learning to enhance its monitoring technologies and develop next-gen wearables [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the technology's performance, particularly in critical care settings [9] - The company anticipates a strong finish for the year, driven by continued demand and new customer installations [15] - Adjusted EPS guidance was raised, reflecting strong operational improvements and share repurchases [20][22] Other Important Information - The sale of Sound United's assets was completed, with net proceeds of $328 million used for debt repayment and share repurchases [19] - The company plans to provide more details on its product pipeline and long-term financial outlook at the upcoming Investor Day on December 3rd [69] Q&A Session Summary Question: What can be expected for the rest of the year and potential for further outperformance? - Management highlighted strong contracting performance and expected a strong finish in Q4, which would drive consumable growth [25] Question: How does the share buyback impact profitability? - The increase in EPS guidance was partly due to share buybacks and operational improvements, contributing to margin expansion [27] Question: What is the status of enhancing commercial excellence? - The company is focusing on enhancing resources for specialty categories and expects to see momentum pick up into next year [29] Question: Can you provide details on share gains with Philips? - The company noted that it still has a low market share within Philips' installed base and sees significant growth opportunities [32] Question: What is the outlook for consumables growth? - Management indicated that unusual year-over-year comparisons affected consumables growth, but they expect normalization and acceleration in Q4 [40][41] Question: What is the impact of the distributor model shift? - The shift to a distributor model in some international markets is expected to create a $6 million revenue headwind but is seen as a long-term growth strategy [42][44] Question: What is the broader capital allocation framework post-Sound United sale? - The company plans to focus on share repurchases and tuck-in technologies to augment its portfolio [63]

Core Insights - Koninklijke Philips (PHG) reported earnings of €0.19 per share, remaining flat year over year, with sales decreasing 1.7% to €4.3 billion, but comparable sales increased 3% driven by growth across all segments [1][8] - The company achieved an 8% increase in comparable order intake year over year in the reported quarter, indicating solid market demand [1][8] Sales Performance - Comparable sales in growth geographies increased by 3%, with Personal Health driving a 5% growth, while Mature geographies also saw a 3% increase, primarily from North America [2] - Diagnosis & Treatment revenues declined 3.3% to €2.08 billion, with comparable sales up 1%, while Connected Care revenues decreased 0.9% to €1.20 billion, but comparable sales increased 5% [3] - Personal Health revenues grew 5.7% to €883 million, with comparable sales up 11%, reflecting strong performance in both growth and mature geographies [4] Operating Performance - Gross margin contracted by 140 basis points to 44.4%, while general & administrative expenses increased slightly to 3.6% of sales [5] - Philips achieved €222 million in savings through cost management and productivity initiatives, with adjusted EBITA increasing 2.9% to €531 million and EBITA margin expanding 50 basis points to 12.3% [6][8] - Diagnosis & Treatment's adjusted EBITA margin contracted to 11.8%, while Connected Care's margin expanded to 11.4% [7] Financial Position - As of September 30, 2025, cash and cash equivalents were €1.91 billion, total debt was €8.385 billion, and operating cash flow was €327 million, significantly up from €192 million year over year [10] - Free cash flow improved to €172 million compared to €22 million in the previous year [10] Future Guidance - Philips expects 1-3% growth in comparable sales for 2025, with adjusted EBITA margin projected between 11.3% and 11.8% [11]

Core Insights - Philips Ultrasound is laying off 33 employees from its Bothell, Washington location [1] Company Summary - The layoffs indicate a potential restructuring or cost-cutting measure within Philips Ultrasound [1] - The specific reasons for the layoffs have not been disclosed, but they may reflect broader trends in the healthcare technology sector [1]

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN ISSUER (Address of principal executive offices) Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 4, 2025 KONINKLIJKE PHILIPS N.V. (Exact name of registrant as specified in its charter) Royal Philips (Translation of registrant's name into English) The Netherlands (Jurisdiction of incorporation or organization) Prinses Irenestraat 59, 1077 WV Amsterdam, The Netherlands Indicate by check mark w ...

Financial Data and Key Metrics Changes - Order intake grew by 8%, marking the fourth consecutive quarter of improvement, reflecting robust demand and disciplined execution [4] - Comparable sales growth increased to 3% year-on-year, with all businesses contributing to growth [4] - Adjusted EBITDA margin expanded by 50 basis points to 12.3%, despite the impact of tariffs [4][24] - Free cash flow for the quarter was EUR 172 million, representing a EUR 150 million improvement year-over-year [28] Business Line Data and Key Metrics Changes - Personal Health saw a strong performance with an 11% increase in comparable sales, driven by robust demand across all regions [22] - Diagnosis & Treatment (D&T) experienced a 1% year-over-year increase in comparable sales, with image-guided therapy showing solid growth [19][20] - Connected Care's comparable sales grew by 5%, supported by strong growth in monitoring solutions [21] Market Data and Key Metrics Changes - North America was a key growth driver, with strong demand for hospital patient monitoring solutions [8][16] - In China, tender activity has been gradually increasing, but market growth remains subdued due to centralized procurement challenges [17][59] - Capital spending in Europe and Latin America remains stable, while India and Saudi Arabia continue to invest in healthcare and digitization [17] Company Strategy and Development Direction - The company aims to maintain momentum with disciplined execution into the fourth quarter to achieve full-year plans [5] - Continued focus on innovation and productivity improvements, leveraging AI to enhance operational efficiency [26] - The company is actively engaging with industry associations and authorities to advocate for patients and ensure access to care [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year commitments, with expectations for comparable sales growth in the range of 1%-3% [29] - The company anticipates a net impact of EUR 150 million-EUR 200 million from tariffs after substantial mitigation efforts [24] - Management remains cautious about the near-term outlook for China but is optimistic about long-term growth potential [17][59] Other Important Information - The company passed six out of nine FDA inspections with no observations, reflecting progress in quality systems [12] - A recent FDA warning letter is being addressed with full remediation efforts, with no expected impact on commercial operations [14][58] Q&A Session Summary Question: Future Price Increases - Management indicated that price increases may occur due to inflation and the inherent value of innovations, but growth remains a priority [35][37] Question: Personal Health Performance - Personal Health's strong sales were partially aided by a low comparable base in China, with no restocking observed [39] Question: Maintaining Productivity Momentum - Management is focused on delivering strong performance in 2025, with confidence in mitigating tariff impacts [43][44] Question: Order Timing in D&T - Management noted uneven order timing, with expectations for D&T to step up in Q4 [49][50] Question: Impact of GE's Decision - Management sees potential for competitive positioning improvement due to GE's decision to sell its Chinese business [67][69] Question: Tariff Impact on Margins - Management acknowledged that tariffs will have a larger impact next year but remains focused on improving margins [76] Question: VBP Impact in China - Management confirmed that the procurement rollout affects their business, contributing to slower market growth [78]

Financial Data and Key Metrics Changes - Order intake grew by 8%, marking the fourth consecutive quarter of improvement, reflecting robust demand and disciplined execution [4] - Comparable sales growth increased to 3% year-on-year, with all businesses contributing to growth [4] - Adjusted EBITDA margin expanded by 50 basis points to 12.3%, despite the impact of tariffs [4][5] - Free cash flow for the quarter was EUR 172 million, representing a EUR 150 million improvement year-over-year [29] - Net income rose to EUR 187 million, driven by higher earnings [28] Business Line Data and Key Metrics Changes - Personal Health segment saw an 11% increase in comparable sales, with strong demand across all regions [22] - Diagnosis and Treatment (D&T) segment had a 1% year-over-year sales increase, with Image-Guided Therapy showing solid growth [18][19] - Connected Care segment experienced a 5% growth in comparable sales, driven by strong monitoring solutions [21] - Adjusted EBITDA margin for Connected Care improved by 410 basis points to 11.4% [21] Market Data and Key Metrics Changes - North America was a key growth driver, with double-digit order growth and strong demand for hospital patient monitoring solutions [6][15] - China showed subdued demand amid cautious consumer sentiment, although tender activity has been gradually increasing [16] - Capital spending remained stable in Europe and Latin America, while India and Saudi Arabia continued investing in healthcare [16] Company Strategy and Development Direction - The company aims to maintain momentum with disciplined execution into the fourth quarter to achieve full-year plans [5] - Continued focus on innovation and productivity improvements, leveraging AI to enhance operational efficiency [26] - The company is committed to mitigating tariff impacts through inventory management and cost discipline [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year commitments, with expectations for comparable sales growth in the range of 1%-3% [30] - The company anticipates an adjusted EBITDA margin at the upper end of the 11.3%-11.8% range for 2025 [30] - Management remains cautious about the near-term outlook for China but is optimistic about long-term growth potential [16] Other Important Information - The company passed six out of nine FDA inspections with no observations, reflecting progress in quality systems [12] - A warning letter from the FDA was acknowledged, but management does not expect it to impact commercial operations [58][90] Q&A Session Summary Question: Future price hikes and contribution from China - Management indicated that pricing opportunities exist but will not impede growth, emphasizing margin expansion through innovation and productivity [39] - Personal Health sales were strong, with no restocking effect in China, and broad-based growth across all businesses [41] Question: Maintaining productivity momentum into 2026 - Management expressed confidence in continuing to offset tariff impacts and improving margins, with more details expected at the capital markets day [46] Question: Order timing in D&T and impact of VBP in China - Management noted that order timing is uneven, with expectations for D&T to step up in Q4, while VBP is affecting the market dynamics in China [50][81] Question: Impact of GE's decision to sell its Chinese business - Management highlighted competitive positioning and innovation as key differentiators, with a focus on customer preference for their platforms [72] Question: Currency headwinds for next year - Management expects some currency headwinds in Q4, but has successfully offset impacts in Q3 [76] Question: Downgrade in D&T guidance - Management confirmed that the downgrade is primarily related to China, with longer conversion cycles also contributing [88]

Financial Data and Key Metrics Changes - Order intake grew by 8%, marking the fourth consecutive quarter of improvement, reflecting robust demand and disciplined execution [4][5] - Comparable sales growth increased to 3% year-on-year, with adjusted EBITDA margin expanding by 50 basis points to 12.3% despite tariff impacts [4][5][24] - Year-to-date order book is up 6% compared to last year, with free cash flow expected to be between EUR 0.2 billion and EUR 0.4 billion for the full year [5][30] Business Line Data and Key Metrics Changes - Personal Health segment saw an 11% increase in comparable sales, driven by strong demand across grooming, oral healthcare, and childcare [21][22] - Connected Care achieved 5% comparable sales growth, supported by strong monitoring solutions, while Diagnostic Imaging experienced a modest decline [20][21] - Diagnosis and Treatment (D&T) comparable sales improved by 1% year-over-year, with Image-Guided Therapy showing solid growth [18][19] Market Data and Key Metrics Changes - North America remains a key growth driver, with strong demand for hospital patient monitoring solutions and a double-digit order intake growth [6][16] - In China, tender activity is gradually increasing, but centralized procurement is causing longer processing times and tougher competition [17][44] - Capital spending remains stable in Europe and Latin America, while India and Saudi Arabia continue to invest in healthcare and digitization [17] Company Strategy and Development Direction - The company is focused on driving measurable improvements in collaboration with global regulators and reinforcing trust among stakeholders [14] - Continued investment in innovation is expected to fuel growth, with a strong emphasis on AI to enhance productivity across various segments [26] - The company plans to showcase progress under its 2023 to 2025 plan at the upcoming capital markets day in February 2026 [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year commitments, with expectations for comparable sales growth in the range of 1%-3% [30][31] - The impact of tariffs is anticipated to be between EUR 150 million and EUR 200 million for the full year, with ongoing mitigation efforts [24][30] - Management remains cautious about the near-term outlook for China but is optimistic about long-term growth potential [17][44] Other Important Information - The company passed six out of nine FDA inspections with no observations, reflecting progress in quality systems [12][13] - Adjusted diluted EPS from continued operations rose to EUR 0.36, up 13% year-over-year, driven by higher earnings [27] - Free cash flow performance improved significantly, with EUR 172 million reported for the quarter [28] Q&A Session Summary Question: Future price hikes and inflation impact - Management indicated that price increases may occur due to inflationary pressures, but growth remains a critical focus [34] Question: Contribution of China to Personal Health sales - Management clarified that there was no restocking effect in China, and broad-based growth was observed across all businesses [35] Question: Maintaining productivity momentum into 2026 - Management expressed confidence in continuing productivity improvements, with a focus on mitigating tariff impacts [36] Question: Order timing in D&T and diagnostic imaging sales outlook - Management noted that order timing is uneven, with expectations for improvement in Q4 [38] Question: Impact of Section 232 on imaging and connected care - Management is actively engaging in discussions regarding tariffs and is preparing to mitigate any potential impacts [40][41] Question: GE's decision to sell its Chinese business - Management highlighted competitive positioning and innovation as key differentiators in the market [49] Question: Currency headwinds for next year - Management expects some currency headwinds in Q4, which will be factored into future guidance [50] Question: Downgrade of D&T sales guidance - Management confirmed that the downgrade is primarily related to China, with longer conversion cycles also impacting sales [54][56]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

2 Important information Forward-looking statements and other important information Third quarter 2025 results Roy Jakobs, Chief Executive Officer Charlotte Hanneman, Chief Financial Officer November 4, 2025 Table of contents | Third quarter 2025 performance | 4 | | --- | --- | | 2025 outlook | 19 | | Financial appendix | 23 | © Koninklijke Philips N.V. This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with ...

Philips order intake climbed 8% in the third quarter amid robust demand for the manufacturer’s medical devices in the US https://t.co/OLJFhi7zHs ...